SCHEMBL1574880

SCHEMBL1574880

CCCN(c1ccccc1)C1CN(C(=O)Nc2cccc3ccccc23)C1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 14/20 0.54
ALDH1A1 P00352 8/20 0.54
HSD17B10 Q99714 7/20 0.54
POLB P06746 2/20 0.52
LMNA P02545 2/20 0.49
USP2 O75604 1/20 0.49
ALOX15 P16050 1/20 0.49
MAPK1 P28482 1/20 0.49
TSHR P16473 1/20 0.48
CNR1 P21554 1/20 0.47
CNR2 P34972 1/20 0.47
TAAR1 Q96RJ0 1/20 0.46
EPHX1 P07099 1/20 0.44
KMT2A Q03164 2/20 0.44
PKM P14618 1/20 0.43
NPC1 O15118 2/20 0.43
MEN1 O00255 1/20 0.43
RAB9A P51151 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574559 0.91 KDM4E (0.56) KDM4EALDH1A1HSD17B10POLBLMNA
SCHEMBL1575080 0.86 KDM4E (0.58) KDM4EALDH1A1HSD17B10POLBLMNA
SCHEMBL1575082 0.85 GAA (0.46) LMNAKMT2A
SCHEMBL1574829 0.85 TAAR1 (0.48) KDM4EALDH1A1POLBLMNATSHR
SCHEMBL1574697 0.84 KDM4E (0.56) KDM4EKMT2ANPC1RAB9A
SCHEMBL1575191 0.84 GAA (0.49) KDM4EALDH1A1POLBLMNAALOX15
SCHEMBL1574621 0.83 KDM4E (0.56) KDM4EALDH1A1HSD17B10POLBLMNA
SCHEMBL1575336 0.83 HPGD (0.47) KDM4EALDH1A1TSHRNPC1RAB9A
SCHEMBL1574613 0.82 ALDH1A1 (0.50) ALDH1A1HSD17B10POLBLMNAKMT2A
SCHEMBL1574440 0.82 KDM4E (0.60) KDM4EALDH1A1HSD17B10POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB KDM4E 516/4885ALDH1A1 1445/4885HSD17B10 1325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.